News Quantified

AKRO – akero therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.

Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $65.00 price target on the stock.

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 [Yahoo! Finance]

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

-5.1%

MISS

-0.8%

BEAT

Form 4 Akero Therapeutics, Inc. For: Nov 15 Filed by: Yale Catriona

Form SC 13G/A Akero Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC

Form SC 13G/A Akero Therapeutics, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Form SC 13G/A Akero Therapeutics, Inc. Filed by: RTW INVESTMENTS, LP

Form SC 13G/A Akero Therapeutics, Inc. Filed by: ALKEON CAPITAL MANAGEMENT LLC

Top News Gainers

3/30 Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001 23.4%

4/9 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 15.2%

3/16 Form 10-K Akero Therapeutics, Inc. For: Dec 31 14.7%

6/19 Form 3 Akero Therapeutics, Inc. For: Jun 19 Filed by: Cheng Andrew 13.4%

4/24 Akero Therapeutics (NASDAQ: AKRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $22.00 price target on the stock. 13.1%

6/25 Form 4 Akero Therapeutics, Inc. For: Jun 24 Filed by: Harrison Seth Loring 9.7%

12/19 Form 4 Akero Therapeutics, Inc. For: Dec 17 Filed by: Atlas Venture Fund XI, L.P. 7.6%

6/20 Form 424B4 Akero Therapeutics, Inc. 7.5%

4/13 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.5%

4/7 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%

Top News Decliners

3/16 Q4/2019 12/31/2019 EPS -0.550 ZacksConsensus -0.580 ActVsEst 0.030 - Beat -31.4%

1/21 Form 4 Akero Therapeutics, Inc. For: Jan 16 Filed by: Versant Venture Capital VI, L.P. -17.4%

3/18 Akero Therapeutics (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. -14.8%

9/6 Form 8-K Akero Therapeutics, Inc. For: Sep 05 -13.8%

3/6 Form 4 Akero Therapeutics, Inc. For: Mar 04 Filed by: Adelman Robert J -9.7%

12/31 Form 4 Akero Therapeutics, Inc. For: Dec 27 Filed by: Versant Venture Capital VI, L.P. -9.5%

1/2 Form 4 Akero Therapeutics, Inc. For: Dec 31 Filed by: Atlas Venture Fund XI, L.P. -8.7%

3/31 Form 8-K Akero Therapeutics, Inc. For: Mar 31 -7.8%

12/13 Form 4 Akero Therapeutics, Inc. For: Dec 13 Filed by: Rolph Timothy -7.8%

1/14 Form 4 Akero Therapeutics, Inc. For: Jan 13 Filed by: Adelman Robert J -6.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day